Prognosis and management of cryptococcal meningitis in patients with human immunodeficiency virus infection

Joshua Rhein
David R Boulware
Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, USA

Abstract: Cryptococcal meningitis has emerged as one of the most frequent and deadly opportunistic infections in patients with human immunodeficiency virus (HIV). Cryptococcosis has become the most common cause of adult meningitis in many parts of Africa, where it now rivals tuberculosis in all-cause mortality. While expanding access to antiretroviral therapy in many resource-limited settings has led to improvements in long-term prognosis, early mortality from HIV-associated cryptococcal meningitis remains unacceptably high. Successful management of cryptococcal meningitis is often hindered by unsatisfactory antifungal regimens or by poor control of elevated cerebrospinal fluid pressures. Immune reconstitution inflammatory syndrome also frequently complicates cryptococcal meningitis in patients with acquired immune deficiency syndrome (AIDS) initiating antiretroviral therapy, and the optimal timing of antiretroviral therapy remains unclear. The optimal initial regimen of amphotericin B and flucytosine is difficult to administer and is often not available in resource-limited settings, where cryptococcal meningitis is most prevalent. Fluid and electrolyte coadministration with amphotericin B is essential to minimizing iatrogenic comorbidities. Fortunately, several new approaches have been leading the way toward improving care for cryptococcal meningitis patients in resource-limited settings. Innovative trials utilizing different combinations of antifungal therapy are reviewed, and we summarize the efficacy of different induction regimens. Universal cryptococcal antigen screening of AIDS patients, combined with new point-of-care testing, has the potential to improve the early diagnosis of cryptococcal meningitis markedly in resource-limited settings.

Keywords: human immunodeficiency virus, acquired immune deficiency syndrome, cryptococcal meningitis, immune reconstitution inflammatory syndrome, antiretroviral therapy, antifungal therapy

Introduction
Cryptococcal meningitis is an invasive fungal infection of the central nervous system caused by the encapsulated yeast, Cryptococcus neoformans. The major predisposing factor in the development of cryptococcosis is profound cell-mediated immune deficiency, seen most commonly with advanced human immunodeficiency virus (HIV) infection. Though recognized a century ago, Cryptococcus became a major human pathogen with the emergence of the acquired immune deficiency syndrome (AIDS) epidemic.1,2 Whereas the introduction and increased availability of initially triazole-based antifungal therapy3 and later combination HIV antiretroviral therapy has decreased the incidence of cryptococcal meningitis in many high-income countries,4,5 the incidence of and mortality related to cryptococcal meningitis remain exceedingly high worldwide, particularly in settings where access to antiretroviral therapy is still limited.
The global burden of HIV-associated cryptococcal disease is estimated at nearly one million cases annually. While long-term survival has improved with widespread use of antiretroviral therapy in high-income countries, early mortality remains high. Furthermore, expanding access to antiretroviral therapy in resource-limited settings has not yet led to compelling improvements in mortality, with 10-week mortality rates between 24% and 37%, even under optimal research conditions. Early mortality rates are often >50% in routine practice where access to diagnostics or medications is limited or unavailable, intracranial pressure is uncontrolled, or in settings where other barriers to the management of cryptococcal meningitis exist.

The highest burden of cryptococcal meningitis is in sub-Saharan Africa, where cryptococcal meningitis is the most frequent cause of adult meningitis. Recent estimates place cryptococcal meningitis as a leading cause of death among people with AIDS, accounting for approximately 20% of all deaths among HIV-infected individuals in Africa. To put this into perspective, these estimates suggest that cryptococcal meningitis accounts for as many or more deaths in Africa than tuberculosis.

**Presentation and prognosis of cryptococcal meningitis in HIV infection**

HIV-associated cryptococcal meningitis has a slowly progressive subacute onset, typically presenting as a meningoencephalitis in severely immunocompromised persons. Cryptococcal meningitis generally presents (about 95%) in persons with a CD4 count < 100 cells/µL, and cryptococcal meningitis is the first AIDS-defining illness in the majority. In general, cryptococcal meningitis should be considered in any patient with advanced HIV infection and symptoms referable to the central nervous system. The most common symptoms encountered include fever, malaise, and headache. Stiff neck, vomiting, visual disturbances, and altered mental status are encountered less frequently initially and typically reflect more advanced disease. Altered mental status at presentation is consistently the clinical feature most strongly associated with a poor clinical outcome. Disseminated disease is more likely with concomitant cough, dyspnea, or cutaneous lesions, most often resembling molluscum contagiosum. Specific signs on physical examination are often lacking, but may include meningismus, papilledema, and cranial nerve palsies (particularly of cranial nerve VI) in advanced disease. Cranial nerve VI palsy is strongly associated with the presence of increased intracranial pressure > 20 cm H₂O.

Persons living with AIDS generally have a higher fungal burden and a greatly reduced inflammatory response as compared with non-HIV-infected persons with cryptococcal meningitis, such as organ transplant recipients, resulting in contrasting clinical, laboratory, and histopathologic features. As such, traditional markers of central nervous system inflammation, such as fever and nuchal rigidity, are often underwhelming in AIDS-related cryptococcal meningitis, usually not occurring until late in the disease course, if at all. Conversely, raised intracranial pressure, which appears to correlate with a high fungal burden, is a major feature in HIV-associated cryptococcal meningitis. As a result, clinical parameters associated with elevated intracranial pressure feature prominently. The lack of an inflammatory response, combined with overwhelming cryptococcosis and extensive brain parenchymal involvement, often with silent multiorgan dissemination, also characterizes the histopathologic findings at the time of autopsy in patients who have died with cryptococcal meningitis. Based on autopsy findings and anatomical locations of paradoxical immune reconstitution inflammatory syndrome (IRIS), silent disseminated cryptococcosis is often the rule, rather than the exception.

While meningitis is the most common manifestation, cryptococcosis can also present without meningitis. In two cohort studies of patients presenting with pulmonary syndromes, cryptococcosis was diagnosed in 13% in Thailand by serum antigen testing and in 11% in Uganda by fungal culture of bronchoalveolar lavage fluid. In both of these cohorts, cryptococcosis was never clinically suspected. Pulmonary cryptococcosis is likely substantially underdiagnosed and often misdiagnosed as smear-negative tuberculosis. Additionally, cryptococcosis can be associated with a nondifferentiated sepsis syndrome. In a prospective multisite sepsis study in Uganda, *C. neoformans* was the fourth most common microorganism isolated from aerobic bacterial blood cultures in persons presenting with sepsis criteria.

The sepsis and pneumonia studies are illustrative in that cryptococcosis was an incidental unexpected finding, which is often the case when one is not specifically pursuing cryptococcal diagnostics. These observations also lend further support to a pathogenic model of primary cryptococcosis occurring in sequential, though often overlapping, stages, whereby inhalation of yeast cells or spores leads to an initial pulmonary infection, followed by fungemia, and finally seeding of the meninges. This model is further supported by trials demonstrating a high prevalence (34%–39%) of pneumonia by chest imaging on initial presentation. Furthermore, concomitant pulmonary involvement is an independent risk factor for mortality in...
cryptococcal disease. In a large retrospective analysis in the US, for example, respiratory failure, pneumonia, and syncope were all strongly associated with inpatient mortality.

Diagnosis

The laboratory diagnosis of cryptococcal meningitis is generally straightforward, though in practice early diagnosis can be hindered by the insidious nature of cryptococcosis, the overall lack of specific early symptoms, lack of knowledge of HIV status, and empiric treatment for possible alternative diagnoses, eg, malaria, tuberculosis, and pneumonia. The high fungal burden usually seen in HIV-associated cryptococcal meningitis results in characteristic cerebrospinal fluid findings, and analysis of the cerebrospinal fluid with India ink staining usually (approximately 80%–85%) suggests the diagnosis. In cases of suspected cryptococcal meningitis, lumbar puncture with measurement of the opening pressure is therefore of the utmost urgency.

Cerebrospinal fluid parameters

The initial opening pressure is elevated (>20 cm H₂O) in about 70% of patients in Africa and 50%–60% in the US. The India ink stain can be used to identify encapsulated yeasts on direct microscopic examination of cerebrospinal fluid. This stain accentuates the polysaccharide capsule of C. neoformans, and is 80%–85% sensitive in HIV-related cryptococcal meningitis. There is a characteristic lack of cerebrospinal fluid pleocytosis (usually <50 white blood cells/µL) in AIDS patients, and up to 25% of patients may have normal white blood cell counts and normal protein levels in their cerebrospinal fluid. Furthermore, the lack of inflammatory markers in cerebrospinal fluid on initial lumbar puncture is an indicator of poor prognosis in cryptococcal meningitis. Glucose levels in cerebrospinal fluid can also be variably low or normal. Blood cultures can frequently be positive in cases of AIDS-associated cryptococcosis. Often this is incidental growth in aerobic bacterial blood culture or mycobacterial blood culture systems; however, fungemia likely reflects a minority of overall cases in comparison with cryptococcal antigen (CRAG) testing. The diagnosis of cryptococcal meningitis is conclusively established by isolating the organism on cerebrospinal fluid culture, yet antigen testing with results immediately available has surpassed culture as a diagnostic tool to guide initial therapy.

Cryptococcal antigen

The detection of CRAG in cerebrospinal fluid or serum is an important diagnostic tool. Commercially available tests for detection of CRAG, either by latex agglutination or by enzyme immunoassay, have been available for several years. The presence of CRAG in cerebrospinal fluid not only helps confirm the diagnosis, but can provide useful prognostic information. For example, initial CRAG titer > 1:1024 are predictive of higher acute mortality. Therefore, CRAG testing should always be performed on cerebrospinal fluid for all patients with HIV suspected of having meningitis, regardless of other cerebrospinal fluid parameters. A normal cerebrospinal fluid profile (with normal white blood cell and protein levels) does not exclude cryptococcal meningitis. The CRAG test is both sensitive (93%–100%) and specific (93%–98%) in cerebrospinal fluid. Importantly, in very early disease with a low fungal burden, the CRAG test appears to be more sensitive than culture, particularly if a small volume of cerebrospinal fluid is cultured (<1 mL). Testing for serum CRAG is also another diagnostic option in suspected cryptococcal meningitis because the sensitivity of serum CRAG is ≥99% when the cerebrospinal fluid CRAG is positive. Serum antigenemia in HIV-infected patients with any central nervous system symptoms should prompt a lumbar puncture for further cerebrospinal fluid evaluation and treatment, particularly measurement and control of intracranial pressure. Conversely, when unexpected or discordant cerebrospinal fluid results are seen (cerebrospinal fluid CRAG positive, cerebrospinal fluid culture negative), serum CRAG testing can help confirm the diagnosis.

High initial CRAG titers generally correlate with high fungal burden by quantitative culture. However, the correlation is roughly accurate but not precise, because the CRAG titer in cerebrospinal fluid is reflective of the presence of a shed cryptococcal capsule (from viable and/or dead organisms), and this capsule shedding has strain to strain variability. The lack of CRAG titer precision has generally implied that ±1 dilution of the titer is considered to be equivalent. Enzyme-linked immunoassay measurement of CRAG (Immuno-Mycologics Inc, Norman, OK) is another technique utilized which can provide more precision. While high CRAG titers are associated with poor outcome, and the titers generally fall with successful treatment, historically titers have not been used in the management of acute cryptococcal meningitis. However, residual CRAG burden when starting antiretroviral therapy appears to be a risk factor for paradoxical IRIS.
cryptococcosis unrelated to the central nervous system, necessitates a dependent period of incubation of typically ≥72 hours, requires an adequate volume of a clinical specimen, and requires a laboratory infrastructure that is typically not present in resource-limited settings. The yeast grows readily at room temperature on Sabouraud dextrose agar and identification is not challenging. This agar is inexpensive but not always available. CRAG assays by latex agglutination or enzyme immunoassay are highly sensitive and specific, less labor-intensive and time-intensive than cultures, and can be utilized from either cerebrospinal fluid or serum specimens. Several factors prohibit the widespread use of CRAG testing in resource-limited settings, including laboratory infrastructure requiring heat inactivation of the sample and electricity, need for refrigeration of reagents, and a cold chain for reagent shipping. Cold chain shipping dramatically increases costs of what should be a relatively inexpensive CRAG latex agglutination assay (less than $5).

Lateral flow assay
For these reasons, efforts have recently been advanced toward the development of an inexpensive point-of-care, lateral flow immunoassay, as advocated by the World Health Organization. In July 2011, the US Food and Drug Administration approved a point-of-care lateral flow immunoassay for the detection of CRAG (Figure 1, Immuno-Mycologics Inc). This CRAG lateral flow immunoassay has a 10-minute processing time, is stable at room temperature, does not require cold chain shipping, and requires minimal technical expertise without the need for a centralized laboratory. Lateral flow immunoassay has performed well when compared with enzyme immunoassay in the testing of serum. Unlike latex agglutination, the lateral flow immunoassay can also be used for other sample types, such as plasma, urine, and possibly whole blood by finger-stick. These tests have the potential to improve the early diagnosis of cryptococcal meningitis markedly in resource-constrained settings.

Treatment of cryptococcal meningitis in HIV infection
The Infectious Diseases Society of America divides the treatment of cryptococcal meningitis into three phases, ie, a two-week induction phase, followed by an eight-week consolidation phase, and an extended maintenance phase thereafter for secondary prophylaxis. The guideline recommendations consider both the optimal medical therapy as

![Figure 1 Cryptococcal antigen lateral flow assay. Reproduced with permission by Immuno-Mycologics Inc, Norman, OK. Notes: This assay is a qualitative or semiquantitative (requires additional dilutions) method for detection of cryptococcal antigen in serum or cerebrospinal fluid. After combining the specimen sample with the diluent, a test strip is inserted, with the results obtained in 10 minutes. Each kit contains 50 test strips, along with the diluent and positive control. Cost from the manufacturer for resource-limited regions is $2 per test.](https://www.dovepress.com/)

---

48

Dovepress

Neurobehavioral HIV Medicine downloaded from https://www.dovepress.com/ by 54.70.40.11 on 20-May-2019

For personal use only.

Powered by TCPDF (www.tcpdf.org)
well as the management of the complications of cryptococcal meningitis frequently encountered (Table 1). Historically, international treatment guidelines have been informed primarily by large multisite clinical trials with endpoints of treatment success and survival at 2 weeks and 10 weeks.

**Induction therapy**

Currently recommended first-line induction therapy for cryptococcal meningitis consists of 2 weeks of amphotericin B in combination with fluconazole. This recommendation is based on the combination of amphotericin-flucytosine leading to better cerebrospinal fluid culture sterilization than amphotericin alone; however, there has never been a published mortality benefit shown with the addition of flucytosine over a series of clinical trials in the 1980s and 1990s. The first large clinical trial directly comparing amphotericin (0.4–0.5 mg/kg/day) and fluconazole (200 mg/day) demonstrated similar overall survival in the pre-antiretroviral therapy era, though there was both lower early mortality and more rapid sterilization of the cerebrospinal fluid with amphotericin as compared with fluconazole. Neither dosage utilized was optimal in retrospect. A second US clinical trial using higher doses of amphotericin (0.7–0.8 mg/kg/day) with or without the addition of fluconazole 100 mg/kg/day subsequently informed the currently accepted guidelines. While the combination of amphotericin and fluconazole appears to be rapidly fungicidal and may have a lower risk of treatment failure than alternative 14-day regimens, the added benefit of flucytosine as a second agent over other antifungals continues to be debated. A recent (as yet unpublished) trial from Vietnam has for the first time demonstrated superior 10-week survival in amphotericin (0.7–1.0 mg/kg/day) plus flucytosine (×2 weeks) versus amphotericin B (×4 weeks) alone and a trend toward better survival in comparison with amphotericin + fluconazole 800 mg/day × 2 weeks. This is the first trial to show a survival benefit over amphotericin alone. However, Loyse et al demonstrated that the microbiologic activity of adding fluconazole 1200 mg/day appears to be very similar to flucytosine and at lower cost, better toxicity profile, and much greater availability in Africa.

**Management with amphotericin B**

Amphotericin is well known for its frequent and often severe side effects. Significant infusion reactions must be anticipated and the tendency toward intravenous line-associated phlebitis necessitates a sizable and experienced nursing commitment over the induction phase. Nursing care is very important. Intravenous lines should be flushed after amphotericin is administered and peripheral intravenous sites rotated every 3 days to minimize thrombophlebitis. Vigorous fluid coadministration of 1–2 L saline/day, along with careful monitoring for renal dysfunction and particularly electrolyte abnormalities (K, Mg, HCO₃) are additional prerequisites. In otherwise relatively young subjects without pre-existing kidney disease or concomitant nephrotoxic medications and appropriate intravenous fluid administration, dosing-limited acute renal failure is actually very rare (<5%) during 2 weeks of amphotericin administration. However, nephrotoxicity does occur without overt creatinine rise, with increasingly cumulative massive losses of potassium and magnesium beginning 5 days after amphotericin initiation. Electrolyte management with amphotericin is essential, and recognized as an essential part of the package of care in World Health Organization treatment guidelines. Whenever amphotericin B deoxycholate is administered, supplemental potassium 40–60 mEq/day and magnesium 8–16 mEq/day are required, with increasing amounts in the second week of amphotericin. Without routine supplementation, the majority of persons will develop severe hypokalemia by the second week of amphotericin, which can be life-threatening.

---

**Table 1 Antifungal treatment recommendations for cryptococcal meningitis in HIV-infected individuals**

<table>
<thead>
<tr>
<th>Timeline</th>
<th>Induction First 2 weeks</th>
<th>Consolidation Next 8 weeks</th>
<th>Maintenance Until immune reconstitution*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preferred regimen</td>
<td>Amphotericin B (0.7–1.0 mg/kg per day) plus fluconazole (100 mg/kg per day)</td>
<td>Fluconazole 400–800 mg per day</td>
<td>Fluconazole 200 mg per day*</td>
</tr>
<tr>
<td>Alternative regimens*</td>
<td>Amphotericin B (0.7 mg/kg per week) plus fluconazole (800–1200 mg per day)</td>
<td>Fluconazole (1200 mg per day) plus fluconazole (100 mg/kg per day) for 6 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fluconazole (1200 mg per day) for 10–12 weeks</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** *CD4 cell count 100 cells/µL, and low or nondetectable viral load for 3 months with minimum of 1 year of antifungal therapy; liposomal amphotericin B (4 mg/kg per day) may be substituted, listed in order of highest recommendation top to bottom; some experts recommend fluconazole doses of 800 mg per day until culture is known to be negative (see text); in clinical situations in which primary recommendations are not available; itraconazole (400 mg per day) or amphotericin B (1 mg/kg per week) if fluconazole intolerant, though inferior regimen.
Increasing doses of amphotericin to 1 mg/kg/day as compared with 0.7 mg/kg/day are more fungicidal. In the absence of underlining renal disease or clinically significant anemia, higher doses may be preferred, although no differences have been observed in mortality between these two doses. Liposomal and lipid complex preparations of amphotericin B are generally considered equally efficacious for treating cryptococcal meningitis and are associated with fewer adverse events and less nephrotoxicity. In one very small trial, more rapid cerebrospinal fluid sterilization was demonstrated with liposomal amphotericin B dosed at 4 mg/kg in comparison with 0.7 mg/kg of deoxycholate amphotericin; however, a larger randomized trial demonstrated no difference in efficacy. Because of better tolerability, lipid formulations are used more frequently in many high-income countries due to lower toxicity. These formulations are considerably more expensive and are universally unavailable in resource-limited settings.

Substantial barriers exist to adhering to the accepted guidelines in resource-limited areas, where cryptococcal meningitis is most prevalent. These include costs and availability of drugs, the requirement for intravenous administration, and the severe and potentially life-threatening toxicity of amphotericin which necessitates hospitalization and close monitoring. Therefore, many centers in Africa and Asia may find it difficult to adhere to recommended induction regimens. In areas where access to amphotericin is limited, for instance, centers rely on fluconazole, which is widely available via the Pfizer Diflucan Donation Program, for initial induction therapy. Fluconazole monotherapy is clearly a suboptimal regimen as compared with amphotericin; however, several recent trials have better informed various alternative options.

Recently, there has been a revolutionary new approach for evaluating the efficacy of cryptococcal induction therapy led by Dr. Thomas Harrison. Bicanic et al have demonstrated in a pooled series of Phase II clinical trials that the rate of cerebrospinal fluid sterilization correlates with clinical outcomes (Figure 2). Specifically, there is an association between early fungal activity during induction therapy and the 2-week and 10-week survival after cryptococcal meningitis. Quantitative culture of cerebrospinal fluid clearance is generally logarithmic over the first 2 weeks, thus the clearance can be estimated by linear regression of log₁₀ colony-forming units (CFU) per mL of cerebrospinal fluid per day of therapy as a unit of measure (ie, change in log₁₀ CFU/mL cerebrospinal fluid/day). This revelation now allows for small innovative clinical trials to estimate the early fungal activity of newer induction regimens with dramatically smaller sample sizes, using early fungal activity as a surrogate marker. Table 2 and Figure 3 summarize early fungal activity data from several recent trials comparing the early fungicidal activity of different induction regimens.

Early trials using fluconazole monotherapy at standard doses of 200–400 mg per day resulted in universally

![Microbiologic rate of CSF cryptococcal clearance association with survival](image-url)

**Figure 2** Kaplan-Meier survival curve by rate of clearance of infection.

**Notes:** More rapid clearance, measured by early fungicidal activity (measured in log₁₀ CFU/mL of cerebrospinal fluid/day), is associated with improved early survival. Patients in top two quartiles for rate of clearance (early fungicidal activity > 0.33 log₁₀ CFU/mL/day) had a higher survival probability than patients in lower quartiles.

**Abbreviations:** CFU, colony-forming units; CSF, cerebrospinal fluid.
Trials comparing early fungicidal activity of induction treatment regimens for cryptococcal meningitis

<table>
<thead>
<tr>
<th>Induction Regimen</th>
<th>EFA ± SD</th>
<th>n</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>AmB + SFC</td>
<td>-0.41</td>
<td>0.22</td>
<td>21</td>
</tr>
<tr>
<td>AmB + fluc (800 mg daily)</td>
<td>-0.38</td>
<td>0.18</td>
<td>22</td>
</tr>
<tr>
<td>AmB + fluc (1200 mg daily)</td>
<td>-0.41</td>
<td>0.35</td>
<td>23</td>
</tr>
<tr>
<td>AmB + voriconazole</td>
<td>-0.44</td>
<td>0.20</td>
<td>13</td>
</tr>
<tr>
<td>AmB (5 days) + fluc (1200 mg daily)</td>
<td>-0.30</td>
<td>0.11</td>
<td>30</td>
</tr>
<tr>
<td>AmB + SFC</td>
<td>-0.49</td>
<td>NA</td>
<td>30</td>
</tr>
<tr>
<td>AmB + SFC + INF-γ</td>
<td>-0.64</td>
<td>NA</td>
<td>60</td>
</tr>
<tr>
<td>SFC + fluc (1200 mg daily)</td>
<td>0.28</td>
<td>0.17</td>
<td>21</td>
</tr>
<tr>
<td>Fluconazole (1200 mg daily)</td>
<td>-0.11</td>
<td>0.09</td>
<td>20</td>
</tr>
<tr>
<td>AmB (7 days) + fluc (1200 mg daily)</td>
<td>-0.39</td>
<td>0.20</td>
<td>19</td>
</tr>
<tr>
<td>AmB (7 days) + fluc (1200 mg daily) + SFC</td>
<td>-0.49</td>
<td>0.15</td>
<td>18</td>
</tr>
<tr>
<td>AmB (0.7 mg/kg/day) + SFC</td>
<td>-0.45</td>
<td>0.16</td>
<td>28</td>
</tr>
<tr>
<td>AmB (1 mg/kg/day) + SFC</td>
<td>-0.56</td>
<td>0.24</td>
<td>29</td>
</tr>
<tr>
<td>Fluconazole (1200 mg daily)</td>
<td>-0.18</td>
<td>0.11</td>
<td>30</td>
</tr>
<tr>
<td>Fluconazole (800 mg daily)</td>
<td>-0.07</td>
<td>0.17</td>
<td>30</td>
</tr>
<tr>
<td>AmB (1 mg/kg/day)</td>
<td>-0.48</td>
<td>0.28</td>
<td>49</td>
</tr>
<tr>
<td>Fluconazole (400 mg daily)</td>
<td>-0.02</td>
<td>0.05</td>
<td>5</td>
</tr>
<tr>
<td>AmB (0.7 mg/kg/day)</td>
<td>-0.31</td>
<td>0.18</td>
<td>14</td>
</tr>
<tr>
<td>AmB (0.7 mg/kg/day) + SFC</td>
<td>-0.54</td>
<td>0.19</td>
<td>12</td>
</tr>
<tr>
<td>AmB + fluc (400 mg daily)</td>
<td>-0.39</td>
<td>0.15</td>
<td>11</td>
</tr>
<tr>
<td>AmB + SFC + fluc (400 mg daily)</td>
<td>-0.38</td>
<td>0.13</td>
<td>15</td>
</tr>
</tbody>
</table>

Abbreviations: EFA, early fungicidal activity (log CFU/mL CSF/day); AmB, amphotericin B (0.7 or 1 mg/kg/day or as indicated); SFC, flucytosine (25 mg/kg 4 times daily); Fluc, flucytosine (doses indicated); Voriconazole (300 mg twice daily; 400 mg twice on day 1); INF-γ, interferon-gamma (100 μg subcutaneously, 2 or 6 doses over induction period).

Table 2 Trials comparing early fungicidal activity of induction treatment regimens for cryptococcal meningitis

Poor outcomes. Fluconazole at ≤400 mg/day is fungistatic, confirmed in a well designed clinical trial demonstrating no change in fungal growth by serial quantitative cultures over 2 weeks with 400 mg/day of fluconazole. Furthermore, the presence of high numbers of viable organisms in cerebrospinal fluid exposed to drug over an extended period could be expected to create a high selective pressure for fluconazole resistance and symptomatic relapse. However, there is a dose-dependent effect with fluconazole. In a study from Mbarela, Uganda, Longley et al showed that fluconazole was more rapidly fungicidal when administered at a dosage of 1200 mg per day versus 800 mg per day. The quantitative rate of cerebrospinal fluid clearance increases as the fluconazole dose is increased, but it is unknown if there is any benefit of increasing fluconazole beyond 1200 mg/day. This is the subject of a current National Institutes of Health-sponsored AIDS Clinical Trial Group trial (NCT00885703). Higher doses of fluconazole were well tolerated in two Ugandan studies, which further validates safety (but not efficacy) data for using doses up to 1600 mg per day. In settings which lack access to amphotericin B and flucytosine, the guidelines now recommend treating with fluconazole 1200 mg divided daily for 12 weeks. Higher doses of fluconazole can induce nausea, so fluconazole doses of 800 mg or above, should be always divided into at least twice daily to avoid this side effect. While fungicidal activity increases with the increasing fluconazole dosing to ≥800 mg/day, the fungicidal activity as yet remains inferior to amphotericin-based regimens.

Other trials have extended the use of high-dose fluconazole to various combinations of induction therapy. A randomized controlled trial in Malawi demonstrated earlier fungicidal clearance and a trend toward improved survival when flucytosine 100 mg/kg/day was added to high-dose fluconazole 1200 mg/day for 6-week oral induction therapy. This approach has been adopted in international guidelines as an alternative recommendation in situations where amphotericin is unavailable or its administration is impossible. However, owing to flucytosine costs and country-level licensing issues, flucytosine is rarely available in resource-limited areas.

Combination amphotericin induction therapy

The combination of amphotericin and adjunctive fluconazole is a more widely used and/or available induction regimen (Table 3). In a trial conducted in Thailand and the US, Pappas et al demonstrated better long-term outcomes for induction therapy with amphotericin plus high-dose fluconazole 800 mg/day compared with amphotericin alone and amphotericin plus fluconazole at lower doses of 400 mg/day. Amphotericin plus fluconazole 800 mg/day is currently the preferred regimen in the absence of flucytosine and has become the standard induction therapy at many centers. Current guidelines recommend 14 days of combination therapy, followed by at least 8 weeks of consolidation therapy with fluconazole 800 mg/day alone. Other trials have expanded this approach to conform to local realities. In a recent prospective cohort study from Uganda, for example, short-course amphotericin 1 mg/kg/day × 5 days plus high-dose fluconazole 1200 mg/day × 14 days was well tolerated with rapid clearance of infection. With routine potassium supplementation of 40 mEq/day, no significant laboratory abnormalities occurred, thus this regimen can be used without laboratory monitoring. Survival in this small prospective trial was similar to that after 2 weeks of amphotericin therapy. A definitive Phase III multisite trial is to commence in 2012 to investigate short-course amphotericin in comparison with a standard 2-week course of amphotericin and an all oral regimen of fluconazole with flucytosine.

Until recently, few trials have directly compared the different amphotericin-based adjunctive combination regi-
mens as induction therapy for HIV-associated cryptococcal meningitis. A recent randomized trial from South Africa compared four different 14-day combination induction regimens. In this trial, there were no statistically significant difference in early fungicidal activity whether subjects received adjunctive fluconazole 800 or 1200 mg daily, flucytosine, or voriconazole in combination with amphotericin B. Of note, adjunctive voriconazole performed similarly to fluconazole as well as flucytosine, but offered no benefit over flucytosine for susceptible strains (>95% susceptible).

Interferon-gamma (INF-\(\gamma\)) is another adjuvant to induction therapy. In a randomized trial conducted in the US and Peru, patients receiving INF-\(\gamma\)1b in addition to amphotericin ± flucytosine induction trended toward a greater proportion having cerebrospinal fluid sterilization at 14 days versus adjunctive placebo. In more recent randomized trial in Cape Town, the addition of short-course INF-\(\gamma\)1b to amphotericin plus flucytosine significantly increased early fungal activity clearance with an approximately 30% relative improvement (~0.64 versus ~0.49 log CFU/mL cerebrospinal fluid/day) as compared with amphotericin plus flucytosine alone. The combination of amphotericin plus oral flucytosine plus subcutaneous INF-\(\gamma\) 100 \(\mu\)g (days 1 and 3) is the most microbiologically active induction therapy yet

![Early fungicidal activity of various induction treatment regimens](image)

**Figure 3** Early fungicidal activity of various induction regimens for cryptococcal meningitis, measured as log10 clearance of yeasts per mL of CSF per day in quantitative CSF culture.

**Notes:** Values are the means with 95% confidence intervals as pooled from Table 2 (relevant citations appear in parentheses in the x-axis). A higher negative value indicates more effective early fungicidal activity.

**Abbreviations:** AmB, amphotericin B; fluc, fluconazole; CFU, colony-forming units; CSF, cerebrospinal fluid; EFA, early fungicidal activity.

### Table 3 Recommended treatment for cryptococcal meningitis in resource-limited settings

<table>
<thead>
<tr>
<th>Medication and dose</th>
<th>~2 weeks(^b)</th>
<th>8 weeks</th>
<th>52 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphotericin (0.7–1.0 mg/kg/day) + second adjunctive agent(^a)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluconazole 800–1200 mg daily</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluconazole 400 mg daily</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluconazole 200 mg daily</td>
<td>Continue until CSF is known sterile(^c)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment phase</th>
<th>Induction</th>
<th>Consolidation</th>
<th>Secondary prophylaxis</th>
</tr>
</thead>
</table>

**Notes:** \(^a\)Flucytosine (SFC) 100 mg/kg/day preferred where available, otherwise fluconazole at 800–1200 mg/day in divided doses. KCl 40–60 mEq/day should be given with amphotericin; \(^b\)optimal duration of initial induction therapy is unknown. In resource-limited regions, the cost-benefit is likely maximal for one week induction with amphotericin B at 1 mg/kg/day coupled with 2 weeks of fluconazole 1200 mg/kg/day as the induction; \(^c\)consider longer duration of induction and consolidation therapy if CSF culture positive at 2 weeks.
observed. Whether this translates into improved survival is not yet known.

**Consolidation and maintenance therapy**

After the completion of 8 weeks of consolidation therapy using fluconazole 400–800 mg/day (Tables 1 and 3), maintenance therapy with fluconazole 200 mg daily should be initiated for long-term chronic suppression. Few trials have investigated what is optimal consolidation therapy. With the recognition that fluconazole 800 mg/day is fungicidal whereas 400 mg/day is fungistatic, the presence of sterile cerebrospinal fluid cultures and initial consolidation therapy dosing become more important considerations. The guidelines recommend repeating a lumbar puncture at 14 days of induction therapy to verify culture sterility (in addition to verifying normal intracranial pressure). Given that the day 14 cerebrospinal fluid culture typically has a low fungal burden, an incubation period of 7–10 days is often needed before cerebrospinal fluid culture with no growth is reliably negative. Thus, we recommend the continuation of fluconazole at 800 mg/day until the 14-day cerebrospinal fluid culture is known to be negative. In effect, this is often until the patient comes back to establish ongoing therapy in the outpatient clinic 1–2 weeks later. This is an ideal time to review the 14-day cerebrospinal fluid culture and to either downwardly adjust the fluconazole dose to 400 mg/day, or if culture-positive, to consider a repeat lumbar puncture to verify that the cerebrospinal fluid is now sterile after having received an additional few weeks of the 800 mg/day dose of fluconazole. If suboptimal induction regimens are used, the guidelines recommend continuation of fluconazole 800 mg/day throughout consolidation.

As Figure 4 demonstrates, the probability of sterilizing the cerebrospinal fluid by day 14 of induction therapy is dependent both on the initial fungal burden and the early fungal activity of the induction regimen used. This is further influenced by the host response to infection, with a paucity of inflammation (ie, normal white blood cells and protein, and lower IFN-γ levels in cerebrospinal fluid) being associated with worse microbiologic clearance. Eventually, this understanding may lead to better customization and personalization of cryptococcal treatment.

![Graph showing predicted CSF quantitative culture clearance for various induction treatment regimens](image-url)

**Figure 4** Predicted mean clearance of cerebrospinal fluid as a function of time for various induction regimens used for cryptococcal meningitis, based on early fungicidal activity (refer to Figure 3).

**Notes:** The initial cerebrospinal fluid colony count in this figure (140,000 CFU/mL = 5.15 log CFU/mL) is the median value (n = 178) from a large ongoing trial (Cryptococcal Optimal ART Timing Trial, NCT01075152). As demonstrated, the average time required for cerebrospinal fluid sterilization can be predicted based on the initial quantitative culture of cerebrospinal fluid and the induction regimen selected. Note that depending on the induction regimen used and the initial fungal burden, clearance by 14 days is not always predicted. This provides the basis for either prolonged induction therapy or higher consolidation therapy (eg, fluconazole 800–1200 mg/day).

**Abbreviations:** 5FC, flucytosine; AmB, amphotericin B; CSF, cerebrospinal fluid; fluc, fluconazole.
Secondary prophylaxis
Prolonged maintenance therapy as secondary prophylaxis is based on a high relapse rate observed after primary therapy was discontinued in the pre-antiretroviral therapy era. The results of two large clinical trials in the 1990s comparing fluconazole with amphotericin and itraconazole established fluconazole as the safest and most effective maintenance therapy. These trials did provide clinical experience with amphotericin and itraconazole as alternative maintenance therapy, though use should be reserved for high-risk patients with multiple relapses, fluconazole resistance, or intolerance to fluconazole. The biggest risk factor for relapse continues to be inadequate fluconazole maintenance therapy, including discontinuation by either the health system or patient-initiated discontinuation.

Maintenance fluconazole therapy can be safely discontinued in patients demonstrating a strong and sustained immunologic response after initiation of antiretroviral therapy. Specific guidelines have been influenced by studies demonstrating a low risk of relapse in symptom-free patients who have completed primary therapy, have a sustained CD4 count > 100 cells/µL (based on two separate measurements 6 months apart), an undetectable viral load, and more than one year of antifungal treatment. In resource-limited settings, where routine viral load monitoring is not available, the World Health Organization recommends continuing maintenance therapy for at least 1 year and until a CD4 threshold of >200 cells/µL has been reached. After discontinuing fluconazole maintenance therapy, relapses are rare with successful immune reconstitution. Relapses can and do occur with immunologic failure and/or interruption of antiretroviral therapy, however, so secondary prophylaxis should be reinstituted if CD4 counts fall below 100 cells/µL or if serum CRAG titers increase by more than fourfold. Serum CRAG titers are not routinely checked, but in a person with a lack of immune recovery with antiretroviral therapy, this might be one surveillance method.

Relapse
Cryptococcal meningitis relapse is defined as a recurrence of symptoms, with recovery of viable organisms from previously sterile cerebrospinal fluid. In addition to reinstituting induction therapy, antiretroviral therapy should be optimized (or introduced if not yet initiated), and a thorough review of medicine adherence and potential drug interactions must be undertaken and addressed, if present. Reinduction therapy with high-dose amphotericin (1 mg/kg/day) for at least 7 days is often needed, followed by higher dose fluconazole 800–1200 mg/day. For refractory disease despite these measures, use of an alternative triazole such as voriconazole or weekly amphotericin should be considered. There are limited published data from resource-limited settings on the management of relapse.

In addition to monitoring closely for relapse, clinicians must also be vigilant for the development of IRIS in patients with cryptococcal meningitis initiating antiretroviral therapy. A patient experiencing recrudescence of symptoms without evidence of ongoing infection (ie, sterile cerebrospinal fluid) is more likely to be experiencing a case of paradoxical cryptococcal IRIS, rather than relapse, as discussed below. It is important to differentiate between IRIS versus cryptococcal meningitis relapse because the therapeutic approach differs depending on the etiology behind recurrent symptoms. Relapse and IRIS are not always mutually exclusive.

Relapse is also distinct from treatment failure, defined as persistence of infection, in which sterility of cerebrospinal fluid has never been achieved. Persistent infection should raise a concern for the development of fluconazole resistance. Susceptibility testing is important in this situation. A minimum inhibitory concentration of ≥16 µg/mL or a threefold increase in minimum inhibitory concentration is suggestive of fluconazole resistance, at which point alternative agents should be considered. Cutoff values for C. neoformans are based on minimal clinical data, though isolates with a minimum inhibitory concentration of ≤8 µg/mL are generally considered susceptible, while dose-dependent resistance should be considered with a minimum inhibitory concentration of 16–32 µg/mL, and resistance should be assumed with a minimum inhibitory concentration of ≥64 µg/mL. The major risk factor for the development of resistance is the use of low-dose fluconazole as induction monotherapy. The fungicidal effect of amphotericin minimizes this risk, and resistance remains low in areas where widespread amphotericin-based induction therapy has been adopted. A switch from fluconazole monotherapy to amphotericin as initial treatment for cryptococcal meningitis, for example, has essentially eliminated the majority (but not all) cases of secondary fluconazole resistance.

Management of intracranial pressure
Irrespective of which primary induction regimen is used, the control of cerebrospinal fluid pressure is of primary importance in the management of AIDS-associated cryptococcal meningitis. As discussed, elevated cerebrospinal fluid pressure is generally related to the high burden of yeast in the cerebrospinal fluid of AIDS patients, which
in turn correlates with increased morbidity and mortality.\textsuperscript{22} The likely mechanism for the increased intracranial pressure in HIV-related cryptococcal meningitis is that a high fungal burden leads to clogging of the arachnoid villi with cryptococcal organisms and their shed polysaccharide capsules, leading to impairment of resorptive function.\textsuperscript{27} The cerebrospinal fluid opening pressure should be measured in any suspected case of cryptococcal meningitis. While it is often recommended that radiologic imaging be performed prior to lumbar puncture to avoid the risk of herniation, especially if focal neurologic signs are present, classic hydrocephalus and mass lesions are rare in HIV patients with cryptococcal meningitis.\textsuperscript{26} Elevated opening pressure on initial lumbar puncture needs to be managed promptly and aggressively by decompression. In most settings, this means serial lumbar punctures on a daily basis until the pressure has normalized (<20 cm H\textsubscript{2}O). Temporary percutaneous lumbar drains or ventriculostomy can be used in patients with persistent elevation. In patients with an initial opening pressure > 25 cm H\textsubscript{2}O, enough volume of cerebrospinal fluid should be removed to reduce the opening pressure to <20 cm H\textsubscript{2}O.\textsuperscript{52}

In a patient with symptomatic cryptococcal meningitis in the absence of manometers, considering removing 30 mL of cerebrospinal fluid is reasonable.\textsuperscript{22,28} Therapeutic lumbar punctures should be repeated daily until cerebrospinal fluid pressures have normalized.

Signs of raised cerebrospinal fluid pressure including headache, altered mental status, meningismus, papilledema, and changes in hearing or vision, should be closely monitored during this period. In patients who have a normal baseline opening pressure, a repeat lumbar puncture should be performed at completion of induction therapy to ensure cryptococcal clearance and to exclude development of increased intracranial pressure. Failure to identify or control raised cerebrospinal fluid pressure according to these guidelines may be neurologically detrimental.\textsuperscript{55} The use of medications other than antifungals to help manage increased intracranial pressure is not useful in HIV-associated cryptococcal meningitis, and should generally be avoided. A randomized trial conducted in Thailand was terminated early when severe metabolic complications developed in patients receiving acetzolamide.\textsuperscript{46} High-dose corticosteroid therapy is also ineffective in controlling elevated cerebrospinal fluid pressure, owing to the absence of inflammatory changes observed in cerebrospinal fluid in patients with AIDS. High-dose corticosteroids are not helpful for decreasing intracranial pressure and have been associated with higher mortality than in those not receiving corticosteroids in uncontrolled trials.\textsuperscript{37} This may have been an observational bias, and a new clinical trial is challenging this well established standard belief. The use of analgesia for cryptococcal meningitis headache should not be used in place of therapeutic lumbar punctures to lower intracranial pressure. Because the fundamental cause of the headache is raised intracranial pressure, treatment of the cause is more effective than ameliorating the symptoms.

**Immune reconstitution inflammatory syndrome**

With the increased availability of antiretroviral therapy in resource-limited areas of the world, IRIS has emerged as a major complication in AIDS patients. In cryptococcal IRIS, rapid immune restoration after initiation of antiretroviral therapy leads to an exaggerated, cell-mediated response to live or dead organisms or shed antigen. The exaggerated inflammatory response observed in IRIS is in stark contrast with primary cryptococcal meningitis, which is characterized by a lack of central nervous system inflammation. Cryptococcal IRIS can occur in two distinct scenarios, ie, “unmasking” disease and “paradoxical” IRIS. Prior case literature reports have at times blended these two scenarios as “IRIS,” but they are distinct. In unmasking IRIS, symptoms first appear after initiation of antiretroviral therapy due to previously unrecognized cryptococcal infection.\textsuperscript{47} This unmasking IRIS form can be thought of as an enhanced response to active infection upon immune reconstitution with antiretroviral therapy. In clinical practice, distinguishing unmasking IRIS from acquisition of new infection in the context of persistent immunodeficiency is impossible.\textsuperscript{37} However, based on CRAG screening studies, it has become more clear that this unmasking IRIS is often unmasking of an existing subclinical, untreated cryptococcal infection in persons who have detectable CRAG in their peripheral blood when starting antiretroviral therapy.\textsuperscript{21,46} Pre-antiretroviral therapy CRAG screening and preemptive treatment can prevent antiretroviral therapy-associated cryptococcosis.\textsuperscript{21,88}

**CRAG screening and early targeted therapy**

Several recent studies have provided further evidence that systematic screening of patients with advanced AIDS with serum CRAG is a valuable strategy for the early detection of cryptococcal meningitis.\textsuperscript{17,21,89,90} Among severely immunosuppressed patients (CD4 count < 100 cells/µL) initiating antiretroviral therapy in these studies, the prevalence of positive serum CRAG screenings ranged from 4% to 12% (Figure 5).\textsuperscript{21,91} Furthermore, asymptomatic cryptococcal
antigenemia has been shown to be an independent predictor of death during the first 12 weeks in community and clinic cohorts. With expanding access to antiretroviral therapy in areas with a high prevalence of cryptococcal meningitis, an increasing proportion of diagnoses of cryptococcal meningitis occur among patients who have recently been started on antiretroviral therapy. This unmasking of subclinical cryptococcosis often occurs within 3 months among patients who had subclinical disease when starting antiretroviral therapy. For these reasons, the 2011 World Health Organization rapid advice recommends universal pre-antiretroviral therapy CRAG screening in all HIV patients with CD4 counts < 100 cells/µL entering HIV care. Long-term, 5-year outcomes of asymptomatic CRAG-positive persons screened and pre-emptively treated have better outcomes than persons who develop symptomatic meningitis. The optimal dose and duration of fluconazole in this situation is unclear, though as discussed previously, higher doses are likely to be more effective. On the basis of the available data, treatment with fluconazole 800 mg/day for 2 weeks, followed by 400 mg/day for 8 weeks, is conditionally recommended by the World Health Organization. This recommendation is currently based on expert opinion.

**Paradoxical IRIS**

Paradoxical IRIS is a scenario in persons with cryptococcal meningitis pre-antiretroviral therapy who are treated and then whose symptoms recur after initiating antiretroviral therapy. This clinically appears as relapse, but cultures are typically sterile. Paradoxical IRIS can be thought of as an exaggerated response to dead fungal elements or persistent antigen following successful treatment of cryptococcal meningitis. Common manifestations of cryptococcal IRIS include relapsing meningitis, lymphadenitis, cutaneous lesions, pneumonitis, and cryptococcomas. The proportion of patients with cryptococcal meningitis that develop IRIS after initiation of antiretroviral therapy ranges from 8% to 45%, and the median time of onset after initiation of antiretroviral therapy is approximately 8 weeks. In contrast with other forms of IRIS, in which severe manifestations are rare, cryptococcal IRIS is associated with substantial morbidity and mortality. It is important to differentiate IRIS from microbiologic relapse, other opportunistic infections, bacterial sepsis, and drug-related side effects. Given that there is no laboratory test available for detection, cryptococcal IRIS is primarily a clinical diagnosis of exclusion. In cryptococcal IRIS, the principal consideration is excluding culture-positive relapse.

Regardless of whether a diagnosis of cryptococcal IRIS can be confirmed with certainty, aggressive control of raised cerebrospinal fluid pressure and optimization of antifungal therapy should ensue as outlined above. No detailed guidelines currently exist regarding the optimal medical management of cryptococcal IRIS. Control of intracranial pressure is likely to be of major importance. In addition, and in contrast with unmasking IRIS or recurrent cryptococcal disease, paradoxical IRIS may require an anti-inflammatory management approach, rather than initiation or change in antifungal medication. Specific recommendations are lacking and management decisions must be individualized according

---

**Figure 5** Cryptoantigen screening based on asymptomatic prevalence by location.  
**Notes:** The reported cross-sectional prevalence rates of asymptomatic antigenemia in various outpatient clinics. Populations of HIV-infected people without a prior history of cryptococcal meningitis are displayed.  
**Abbreviations:** ART, antiretroviral therapy.

---

Minor manifestations not involving the central nervous system often spontaneously resolve within weeks with observation. Discontinuation of antiretroviral therapy is rarely necessary. Corticosteroids, on the other hand, are at times utilized in severe cases of paradoxical cryptococcal IRIS, and several case reports have reported benefit. While no clinical trials have been conducted to validate their use in IRIS associated with cryptococcal meningitis, additional support comes from a randomized trial of prednisone in the treatment of IRIS associated with nonsevere tuberculosis. High-dose corticosteroids are safe to use in HIV-infected patients with controlled viral loads. However, in tropical and subtropical regions, caution is warranted, because up to 5% of patients may have chronic, asymptomatic strongyloidiasis, and corticosteroids may precipitate life-threatening hyperinfection. Thus, there may be a mortality risk of steroids without a survival benefit from treating IRIS.

**Optimal timing of antiretroviral therapy initiation**

The optimal time to initiate antiretroviral therapy in patients with cryptococcal meningitis is unclear. While recent trials have supported earlier initiation of antiretroviral therapy across a range of opportunistic infections (Figure 6), concerns about an increased risk of cryptococcal IRIS are often used as a rationalization for delaying antiretroviral therapy in patients with cryptococcal meningitis. Conversely, long delays in antiretroviral therapy can place patients at risk for progressing immunosuppression and mortality from com-

<table>
<thead>
<tr>
<th></th>
<th>Favors early ART</th>
<th>Favors deferred ART</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td># Events</td>
<td>54</td>
</tr>
<tr>
<td>Pneumocystis pneumonia</td>
<td>28</td>
<td>181</td>
</tr>
<tr>
<td>Bacterial infection</td>
<td>11</td>
<td>41</td>
</tr>
<tr>
<td>Other opportunistic infection</td>
<td>42</td>
<td>194</td>
</tr>
<tr>
<td>Fungal</td>
<td>12</td>
<td>52</td>
</tr>
<tr>
<td>Cryptococcosis</td>
<td>8</td>
<td>41</td>
</tr>
<tr>
<td>Mycobacterial</td>
<td>8</td>
<td>18</td>
</tr>
<tr>
<td>&gt;1 opportunistic infection</td>
<td>30</td>
<td>148</td>
</tr>
<tr>
<td>CD4 &lt; 50</td>
<td>39</td>
<td>196</td>
</tr>
<tr>
<td>CD4 &gt;= 50</td>
<td>15</td>
<td>86</td>
</tr>
</tbody>
</table>

**Figure 6** AIDS progression/death by opportunistic infection versus timing of initiation of ART.

Notes: Figures given as log OR, with 95% confidence intervals, with OR < 1.0 favoring early ART versus deferred initiation of ART. Total, fungal and CD4 < 50 categories represent significance at P < 0.05. Fungal infections include cryptococcal infections and histoplasmosis.

**Abbreviations:** AIDS, acquired immunodeficiency virus; ART, antiretroviral therapy; OR, odds ratio.

substantial barriers exist in adhering to the accepted guidelines in resource-constrained areas of the world where cryptococcal meningitis is most prevalent. Fluconazole is widely available worldwide, and is an essential component through all phases of treatment, though is not preferred for induction monotherapy. Innovative trials utilizing different combinations of antifungal therapy are ongoing, and are leading the way in efforts to improve the care of HIV patients with cryptococcal meningitis, in whom IRIS has emerged as a major complication. The optimal time to initiate antiretroviral therapy in patients with cryptococcal meningitis remains unclear, and trials are underway to answer this question. Systemic screening of AIDS patients with serum CRAG is proving to be a valuable strategy for early detection and targeted treatment of cryptococcal disease.

**Conclusion**

In summary, cryptococcal meningitis is a leading cause of morbidity and mortality in HIV-infected patients, particularly in resource-limited areas of the world. Symptoms typically begin indolently, and can include fever, malaise, and headache. Altered mental status is a marker for advanced disease and is predictor of poor outcome. Analysis of cerebrospinal fluid during primary disease is notable for a lack of inflammation in AIDS patients. The presence of cryptococcal antigen in cerebrospinal fluid or serum is central in the diagnosis of cryptococcal meningitis. New point-of-care testing has the potential to improve early diagnosis of cryptococcal meningitis in resource-limited settings markedly, and has been recommended by the World Health Organization. Updated treatment guidelines have been published that consider the optimal medical therapy in HIV-associated cryptococcal meningitis as well as complications that are frequently encountered in its management. However, substantial barriers exist in adhering to the accepted guidelines in resource-constrained areas of the world where cryptococcal meningitis is most prevalent. Fluconazole is widely available worldwide, and is an essential component through all phases of treatment, though is not preferred for induction monotherapy. Innovative trials utilizing different combinations of antifungal therapy are ongoing, and are leading the way in efforts to improve the care of HIV patients with cryptococcal meningitis, in whom IRIS has emerged as a major complication. The optimal time to initiate antiretroviral therapy in patients with cryptococcal meningitis remains unclear, and trials are underway to answer this question. Systemic screening of AIDS patients with serum CRAG is proving to be a valuable strategy for early detection and targeted treatment of cryptococcal disease.

**Acknowledgment**

Research support for this work was received from the National Institutes of Health, National Institute of Allergy and Infectious Diseases (K23AI073192 to DRB and T32AI055433 to JR).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


